Trialbee and Castor Partner to Democratize Access and Simplify Enrollment to Clinical Trials Globally
21.9.2021 14:58:00 EEST | Business Wire | Press release
Trialbee, the leading enrollment performance company, and Castor, a leading provider of decentralized and hybrid clinical trial solutions, today announced a strategic partnership to accelerate patient enrollment, optimize patient engagement, and reduce site burden for clinical trials globally.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210921005005/en/
Castor and Trialbee’s logical integration allows sponsors to meet enrollment timelines with continuous access to all their study data. Together, the fast-growing companies will expedite patient recruitment and streamline clinical trials through advanced data science and streamlined workflows for patient enrollment, data collection, and engagement. The partnership will diversify patient participation and improve equitable health outcomes for global decentralized and hybrid clinical programs.
“We are excited to partner with Trialbee to improve patient engagement, as well as optimize patient diversity and study inclusivity with real-time insights around patient demographics across all recruitment channels,” said Derk Arts, M.D., Ph.D., CEO & Founder, Castor. “Our partnership provides sponsors a seamless decentralized and hybrid clinical trial solution to manage all their clinical trial touchpoints and expand inclusivity at a global scale.”
Recruiting and retaining qualified clinical trial participants is increasingly difficult as clinical study designs become more complex. According to industry estimates, the amount of patient eligibility in clinical trials has increased approximately 150% in the last decade. As a result, life sciences companies demand a patient matching and enrollment platform that can help them better manage the patient’s journey into a clinical trial while optimizing enrollment outcomes. With Trialbee and Castor’s proven integrations, clinical trial sponsors can seamlessly manage all clinical trial touchpoints while ensuring data quality every step of the way.
“Over 70 percent of potential clinical trial participants live more than two hours away from a trial site, increasing the need for greater scale and reach in patient awareness for today’s trial designs,” said Matt Walz, Chief Executive Officer at Trialbee. “Through our combined capabilities, clinical trials can deploy an end-to-end solution to simplify the patient journey, including early introductions to clinical trials, enrollment performance analytics, and remote data capture for decentralized clinical trials.”
About Trialbee
Trialbee is the leading global data and technology platform for patient matching and enrollment in clinical trials. Trialbee Hive™ operationalizes real world data (RWD) and applies data science to match patients globally. Our enrollment platform simplifies the journey for matched patients to qualify and participate in clinical research. Partnering with Sponsors, CROs, and virtual/decentralized sites, and software providers, Trialbee is achieving patient enrollment goals and driving enhancements in diversity in clinical trial populations. We are the smartest way to match and enroll patients for your clinical trial. For more information, visit http://www.trialbee.com or contact us at solutions@trialbee.com.
About Castor
Castor is a leading provider of decentralized and hybrid clinical trial solutions to democratize research. With the highest-rated eClinical platform for decentralized and hybrid clinical trials, Castor’s plug-and-play platform offers rapid deployment at scale, enabling researchers to create a trial in a matter of clicks, with easy enrollment, consent, and real-world data capture. Castor is bringing human-centered design to the clinical trial process, from recruitment to analysis, and improving the quality, security, and reusability of data for researchers worldwide. For more information, visit www.castoredc.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210921005005/en/
Contact information
Doug Weatherhead
Castor
doug.weatherhead@castoredc.com
Media
Kimberly Ha
KKH Advisors
kimberly.ha@kkhadvisors.com
Rosina Ferrante
Gregory FCA (for Trialbee)
215-344-2113
rosina.ferrante@trialbee.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Wolters Kluwer Named Top Vendor Law Firm SaaS Solution Provider in the DACH Region for 202720.7.2026 10:00:00 EEST | Press release
Wolters Kluwer’s Legal & Regulatory has been recognized as a top vendor for Law Firm SaaS Solutions in the DACH region for 2027, according to the latest Vendor Selection Matrix™ by Research in Action. Kleos, the company's cloud-native legal practice management platform, achieved a shared first-place position in the ranking and received the highest scores for customer satisfaction, value for money and customer recommendation among surveyed law firms in Germany, Austria and Switzerland. The recognition builds on the platform's earlier pan-European leadership position and reinforces Kleos' standing as one of Europe's leading legal practice management solutions. "We are proud to be recognized as a leading provider of Law Firm SaaS Solutions in the DACH region,” said Sergio Liscia, Vice President Legal Software at Wolters Kluwer. “What makes this recognition particularly meaningful is that it reflects the experience of legal professionals themselves. Achieving the highest ratings for custom
IQM and Deutsche Bahn Demonstrate Quantum Algorithm for Railway Scheduling on Real Operational Data20.7.2026 09:00:00 EEST | Press release
IQM Quantum Computers (Nasdaq: IQMX), a global leader in full-stack superconducting quantum computers, today published the results of a research collaboration with Deutsche Bahn, Europe’s largest rail operator, exploring how quantum computing can improve railway scheduling. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260719172592/en/ IQM's whitepaper on hybrid quantum optimization for railway scheduling, developed with Deutsche Bahn. Using a real operational dataset from Deutsche Bahn, a schedule of 190 trips across five German cities translating into roughly 98,500 possible cycles, the two organizations developed and tested a hybrid quantum-classical algorithm designed for enterprise-scale optimization problems. As detailed in a published whitepaper here, the IQM team applied the Quantum Approximate Optimization Algorithm (QAOA) in manageable stages, with the quantum component solving smaller subproblems within a classic
Galderma Launches Alastin ® in Japan and Key Markets Across Asia Pacific, Expanding Its Footprint in the Region20.7.2026 08:00:00 EEST | Press release
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced the launch of Alastin – its premium regenerative skincare brand – across the JPAC region. The brand recently launched in Taiwan, will soon launch in Japan, and has received approval to launch in Singapore and South Korea, with planned market introduction in September and November, respectively. This expansion follows Alastin’s recent launches in China and Australia and underscores Galderma’s continued investment in JPAC, a region characterized by advanced skincare practices and rapid growth in injectable aesthetics.1,2 This is increasing demand for integrated skincare solutions that support skin readiness, recovery and long-term quality.3,4,5 Alastin addresses this need through its range of peri-procedural support and daily skincare products that amplify the skin’s natural regenerative abilities, supporting recovery and enhances visible outcomes of in-demand aesthetic procedures such as energy-based device
Incyte Data to Be Highlighted in Four Rapid Oral Presentations at the European Society for Medical Oncology (ESMO) Congress 2026 Support Efforts to Improve Outcomes in Difficult-to-Treat Cancers17.7.2026 20:10:00 EEST | Press release
Incyte (Nasdaq:INCY) today announced that it will highlight data from several programs in its oncology portfolio in six presentations at the European Society of Medical Oncology (ESMO) Congress 2026, being held October 23 - 27, 2026, in Madrid. “The data at ESMO will further illustrate Incyte’s commitment to advancing innovation for patients with cancer,” said Pablo J. Cagnoni, M.D., President, Incyte and Global Head of Research and Development. "Among the presentations are important updates from our KRAS G12D inhibitor in advanced pancreatic cancer and colorectal cancer, our TGFβR2×PD-1 bispecific antibody in microsatellite stable colorectal cancer and our CDK2 inhibitor in recurrent epithelial ovarian cancer – investigational approaches that reflect our focus on areas where there is significant need for novel therapies." Details on key data presentations at ESMO include: Rapid Oral Presentations INCB161734 (KRAS G12D) Safety and Efficacy of Oral KRAS G12D Inhibitor INCB161734 as Mono
STL Expands Its Optical Connectivity Portfolio in the US with the CONCAT Solution17.7.2026 15:24:00 EEST | Press release
STL Optical Connectivity NA, LLC, (STLOC), a U.S. subsidiary of STL (Sterlite Technologies Ltd.) [NSE: STLTECH], a leading connectivity solutions provider for AI-ready digital infrastructure, today announced that it launched its new advanced FTTH solution, CONCAT, after successfully completing field trials on the networks of one of the largest telecom service providers in the United States. Following successful field validation, CONCAT is now available to digital infrastructure providers seeking faster fiber rollouts with reduced deployment complexity and labor. It enables up to 71% in labor cost savings by eliminating most field splicing through factory-assembled, pre-connectorized fiber segments that deliver plug-and-play installation. CONCAT simplifies fiber deployment by shifting critical fiber preparation and termination into a controlled manufacturing environment ensuring consistent quality, faster installation, and lower operational risk in the field. CONCAT solution is ideal fo
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
